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124Left Atrial Appendage
Occlusion Device
Societal Overview
The Surgeon’s CommentWith great interest we read the American College of
Cardiology/Heart Rhythm Society/Society for Cardio-
vascular Angiography and Interventions (ACC/HRS/
SCAI) left atrial appendage (LAA)occlusion device
societal overview by Masoudi et al. (1) summarizing
the latest data, but also highlighting the some critical
issues of current LAA-occlusion strategies.
In this context, and as mentioned by the expert
panel, the adoption of surgical epicardial LAA-
occlusion strategies appears to be a valid therapy-
option in selected patients. However, unfortunately,
the expert panel just provides very brief and incom-
plete information in this regard.
In the era of the heart-team approach, we would
recommend to further highlight substantial data on
surgical epicardial LAA devices as their clinical evi-
dence is rapidly increasing. First, the experience
with the AtriClip (AtriCure, West Chester, Ohio)
which is currently being utilized in the LAAOS-III
(Left Atrial Appendage Occlusion Study III) trial is
already extensive as it has been applied clinically
since 2007 and has been sold more than 50,000
times since regulatory approval. Second, data from
two prospective but nonrandomized trials suggest an
excellent safety and efﬁcacy proﬁle (2,3) and in
particular, just recently, computed tomography
imaging controlled 3-year follow-up data became
available underlining its efﬁcacy with regards to
complete, but also durable LAA-occlusion (3). These
results are of high importance considering the well-
established problem of substantial leaks or rest-
perfusion associated with the currently available
interventional, endocardial LAA-occlusion devices
such as the WATCHMAN which has been utilized
in the PROTECT-AF (WATCHMAN Left Atrial
Appendage System for Embolic PROTECTion in Pa-
tients With Atrial Fibrillation) and PREVAIL (Evalu-
ation of the WATCHMAN LAA Closure Device in
Patients With Atrial Fibrillation Versus Long Term
Warfarin Therapy) trials (NCT00129545/NCT01182441)
(4). Next, long-term data for the AtriClip are awaited
shortly and most importantly, next-generation de-
vices for minimally invasive thoracoscopic (i.e., stand-
alone) approaches are underway. Safety and feasi-
bility of minimally invasive, thoracoscopic surgicalablation (5) as well as LAA amputation have been
demonstrated and are currently being evaluated
in a phase-II trial (The Stroke Feasibility Study;
NCT01997905). In regard to effective stroke reduction,
more data and ideally a prospective randomized trial
are required.
Current indication for LAA closure is based on a
contraindication to oral anticoagulation. Therefore,
before any type of procedure, patient-speciﬁc
anatomical and morphological considerations are
necessary to determine the ideal strategy and also to
identify potential sub-optimal candidates for trans-
catheter LAA closure. In these cases, we strongly
believe that thinking out of the box is mandatory and
such patients should be evaluated for a minimally
invasive surgical LAA occlusion procedure. As known
from other programs such as TAVI (transcatheter
aortic valve implantation) or Mitral-Clip (Abbott
Vascular, Santa Clara, California), we are convinced
that only a close collaboration between cardiologists
and surgeons (heart-team approach) focusing on a
patient-speciﬁc approach and device selection will
assure a safe, complete, and durable LAA occlusion in
all-comers.*Maximilian Y. Emmert, MD, PhD
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